AXIM Begins Phase 2 Trial of Cannabinoid Chewing Gum for IBS Symptoms
News
AXIM Biotech has initiated a Phase 2 clinical trial evaluating the effectiveness of its CanChew Plus cannabinoid (CBD)-based chewing gum for alleviating symptoms of irritable bowel syndrome (IBS). In the case ... Read more